Skip to content
value.today

Athersys: peers

Change the peers

Athersys beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Athersys, Brainstorm Cell Therapeutics Inc., Enzon Pharmaceuticals, Inc., Inhibikase Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Athersys, Brainstorm Cell Therapeutics Inc., Enzon Pharmaceuticals, Inc., Inhibikase Therapeutics, Inc., Allarity Therapeutics, Inc., Valion Bio, Inc., aTyr Pharma, Inc., Vyome Holdings, Inc side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureAthersysbase
ATHX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Brainstorm Cell Therapeutics Inc.
BCLI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Enzon Pharmaceuticals, Inc.
EZ1.F · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Inhibikase Therapeutics, Inc.
IQT.F · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Allarity Therapeutics, Inc.
ALLR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Valion Bio, Inc.
VBIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
aTyr Pharma, Inc.
ATYR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Vyome Holdings, Inc
HIND · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$14 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8$14 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8$14 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8$14 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one2nd of 8$14 MOct 15, 2026 · Market data6th of 8$14 MOct 30, 2026 · Market data7th of 8$14 MOct 30, 2026 · Market data8th of 8$14 MOct 7, 2026 · Market data1st of 8$14 M8 ranked
Revenue (Better neither way: ranked highest first)$6 MFY2019 · Wikidata1st of 3——————$0 MFY2025 · SEC2nd of 3——$0 MFY2025 · SEC3rd of 3——$0 M3 ranked
Net income (Higher is better)————$-3 MFY2025 · SEC1st of 6$-48 MFY2025 · SEC5th of 6$-11 MFY2025 · SEC4th of 6$-9 MFY2025 · SEC2nd of 6$-74 MFY2025 · SEC6th of 6$-10 MFY2025 · SEC3rd of 6$-11 M6 ranked
Employees (Better neither way: ranked highest first)832019 · Profile1st of 520December 31, 2025 · Profile4th of 5——————52December 31, 2025 · Profile3rd of 558December 31, 2025 · Profile2nd of 518December 31, 2025 · Profile5th of 5525 ranked
Margins and returns
Return on equity (Higher is better)————————-4.6%FY2025 · SEC1st of 570th37th-36.0%FY2025 · SEC2nd of 551st22nd-103.8%FY2025 · SEC4th of 524th10th-91.8%FY2025 · SEC3rd of 527th11th-107.8%FY2025 · SEC5th of 523rd10th————-91.8%5 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————————————43.5×price Oct 15, 2026 · Market data2nd of 290th97th————72.0×price Oct 30, 2026 · Market data1st of 293rd98th————57.8×2 ranked
Price to book (Better neither way: ranked highest first)————————————————1.4×price Oct 15, 2026 · Market data2nd of 428th34th0.8×price Oct 30, 2026 · Market data3rd of 415th15th0.2×price Oct 30, 2026 · Market data4th of 41st1st3.9×price Oct 7, 2026 · Market data1st of 459th70th1.1×4 ranked
Free cash flow yield (Higher is better)————————————————-106.5%price Oct 15, 2026 · Market data2nd of 37th3rd-51.2%price Oct 30, 2026 · Market data1st of 318th7th————-117.6%price Oct 7, 2026 · Market data3rd of 36th2nd-106.5%3 ranked
Financial strength
Debt to equity (Lower is better)————————1.0×FY2025 · SEConly one with it75th66th————————————————————1.0×—
Scorecard
Scorecard (Higher is better)——0 of 1FY2025 · Scorecard7th of 73 of 10FY2025 · Scorecard1st of 71 of 8FY2025 · Scorecard6th of 73 of 14FY2025 · Scorecard3rd of 72 of 9FY2025 · Scorecard2nd of 72 of 13FY2025 · Scorecard5th of 72 of 10FY2025 · Scorecard4th of 720% passed7 ranked
Valuation checks (Higher is better)————————1 of 5FY2025 · Scorecard3rd of 41 of 4FY2025 · Scorecard1st of 41 of 4FY2025 · Scorecard1st of 40 of 4FY2025 · Scorecard4th of 423% passed4 ranked
Growth checks (Higher is better)————0 of 2FY2025 · Scorecard2nd of 50 of 2FY2025 · Scorecard2nd of 50 of 1FY2025 · Scorecard2nd of 5——0 of 2FY2025 · Scorecard2nd of 51 of 2FY2025 · Scorecard1st of 50% passed5 ranked
Profitability checks (Higher is better)————0 of 3FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard1st of 60 of 2FY2025 · Scorecard1st of 60% passed6 ranked
Financial health checks (Higher is better)——0 of 1FY2025 · Scorecard7th of 71 of 3FY2025 · Scorecard4th of 71 of 2FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 71 of 2FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 71 of 2FY2025 · Scorecard1st of 733% passed7 ranked
Shareholder returns checks (Higher is better)————2 of 2FY2025 · Scorecard1st of 40 of 1FY2025 · Scorecard3rd of 41 of 2FY2025 · Scorecard2nd of 4——0 of 1FY2025 · Scorecard3rd of 4——25% passed4 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————————6.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 40.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 426.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 41.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 44.3%4 ranked
Institutions holding (Better neither way: ranked highest first)————————202026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4712026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4174 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————+2.0 pp2026-Q2 against 2026-Q1 · 13F1st of 3——-15.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 3+0.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 3+0.7 pp3 ranked
Dividends
Shareholder yield (Higher is better)————————————————22.9%FY2025 · SEConly one with it98th97th————————————22.9%—
Dividend per share (Better neither way: ranked highest first)————$0.00FY2025 · SEConly one with it——————————$0.00—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Athersys: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Brainstorm Cell Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Enzon Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inhibikase Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Allarity Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Valion Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; aTyr Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vyome Holdings, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Return on equity#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Return on equity: each company's figure and its percentile in its sector and its country
CompanyReturn on equityIn its sectorIn its country
Athersys———
Brainstorm Cell Therapeutics Inc.———
Enzon Pharmaceuticals, Inc.-4.6%FY2025
70th percentile in Healthcaremedian -36.9%, 977 companies
37th percentile in USAmedian 4.8%, 3,580 companies
Inhibikase Therapeutics, Inc.-36.0%FY2025
51st percentile in Healthcaremedian -36.9%, 977 companies
22nd percentile in USAmedian 4.8%, 3,580 companies
Allarity Therapeutics, Inc.-103.8%FY2025
24th percentile in Healthcaremedian -36.9%, 977 companies
10th percentile in USAmedian 4.8%, 3,580 companies
Valion Bio, Inc.-91.8%FY2025
27th percentile in Healthcaremedian -36.9%, 977 companies
11th percentile in USAmedian 4.8%, 3,580 companies
aTyr Pharma, Inc.-107.8%FY2025
23rd percentile in Healthcaremedian -36.9%, 977 companies
10th percentile in USAmedian 4.8%, 3,580 companies
Vyome Holdings, Inc———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$24 M$49 M$73 M$98 M20102012201420162018202020222024Enzon Pharmaceuticals, Inc. $0 MInhibikase Therapeutics, Inc. $0 MValion Bio, Inc. $1 MaTyr Pharma, Inc. $0 MVyome Holdings, Inc $8 M

Rank in the group

1st2nd3rd4th5th201420152016201720182019202020212022202320242025Athersys: 1st of 4 in 2019AthersysEnzon Pharmaceuticals, Inc.: 1st of 2 in 2014Enzon Pharmaceuticals, Inc.: 1st of 2 in 2015Enzon Pharmaceuticals, Inc.: 1st of 2 in 2016Enzon Pharmaceuticals, Inc.: 2nd of 2 in 2017Enzon Pharmaceuticals, Inc.: 2nd of 2 in 2018Enzon Pharmaceuticals, Inc.: 4th of 4 in 2019Enzon Pharmaceuticals, Inc.: 4th of 4 in 2020Enzon Pharmaceuticals, Inc.: 4th of 4 in 2021Enzon Pharmaceuticals, Inc.: 5th of 5 in 2022Enzon Pharmaceuticals, Inc.: 4th of 4 in 2024Enzon Pharmaceuticals, IncInhibikase Therapeutics, Inc.: 3rd of 4 in 2020Inhibikase Therapeutics, Inc.: 2nd of 4 in 2021Inhibikase Therapeutics, Inc.: 4th of 5 in 2022Inhibikase Therapeutics, Inc.: 4th of 4 in 2023Inhibikase Therapeutics, IAllarity Therapeutics, Inc.: 1st of 2 in 2025Allarity Therapeutics, IncValion Bio, Inc.: 3rd of 4 in 2021Valion Bio, Inc.: 3rd of 5 in 2022Valion Bio, Inc.: 2nd of 4 in 2023Valion Bio, Inc.: 2nd of 4 in 2024Valion Bio, Inc.aTyr Pharma, Inc.: 3rd of 4 in 2019aTyr Pharma, Inc.: 2nd of 4 in 2020aTyr Pharma, Inc.: 2nd of 5 in 2022aTyr Pharma, Inc.: 3rd of 4 in 2023aTyr Pharma, Inc.: 3rd of 4 in 2024aTyr Pharma, Inc.: 2nd of 2 in 2025aTyr Pharma, Inc.Vyome Holdings, Inc: 2nd of 2 in 2014Vyome Holdings, Inc: 2nd of 2 in 2015Vyome Holdings, Inc: 2nd of 2 in 2016Vyome Holdings, Inc: 1st of 2 in 2017Vyome Holdings, Inc: 1st of 2 in 2018Vyome Holdings, Inc: 2nd of 4 in 2019Vyome Holdings, Inc: 1st of 4 in 2020Vyome Holdings, Inc: 1st of 4 in 2021Vyome Holdings, Inc: 1st of 5 in 2022Vyome Holdings, Inc: 1st of 4 in 2023Vyome Holdings, Inc: 1st of 4 in 2024Vyome Holdings, Inc
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearAthersysBrainstorm Cell Therapeutics Inc.Enzon Pharmaceuticals, Inc.Inhibikase Therapeutics, Inc.Allarity Therapeutics, Inc.Valion Bio, Inc.aTyr Pharma, Inc.Vyome Holdings, Inc
2025————$0 MSEC1st—$0 MSEC2nd—
2024——$0 MSEC4th——$1 MSEC2nd$0 MSEC3rd$8 MSEC1st
2023———$0 MSEC4th—$1 MSEC2nd$0 MSEC3rd$9 MSEC1st
2022——$0 MSEC5th$0 MSEC4th—$2 MSEC3rd$10 MSEC2nd$11 MSEC1st
2021——$1 MSEC4th$3 MSEC2nd—$1 MSEC3rd—$14 MSEC1st
2020——$0 MSEC4th$1 MSEC3rd——$10 MSEC2nd$11 MSEC1st
2019$6 MWD1st—$0 MSEC4th———$0 MSEC3rd$3 MSEC2nd
2018——$7 MSEC2nd————$9 MSEC1st
2017——$8 MSEC2nd————$10 MSEC1st
2016——$8 MSEC1st————$3 MSEC2nd
2015——$17 MSEC1st————$4 MSEC2nd
2014——$31 MSEC1st————$4 MSEC2nd

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Athersys#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Brainstorm Cell Therapeutics Inc.BCLI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (last known, Jan 5, 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Enzon Pharmaceuticals, Inc.EZ1.F · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (last known, Jul 30, 2023)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Inhibikase Therapeutics, Inc.IQT.F · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (last known, Dec 25, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Allarity Therapeutics, Inc.ALLR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 15, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Valion Bio, Inc.VBIO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • aTyr Pharma, Inc.ATYR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Vyome Holdings, IncHIND · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 7, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • TScan Therapeutics, Inc.TCRX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 29, 2026) · revenue $10 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Pasithea Therapeutics Corp.KTTA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $15 M (Oct 26, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Passage Bio, Inc.PASG · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $15 M (Aug 1, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • BioVie Inc.BIVI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $15 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • PDS Biotechnology CorporationPDSB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $13 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $13 M (Aug 1, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.